Gilead Sciences beats, raises full-year 2026 base business revenue guidance

 

Gilead Sciences beats Q3 2026 estimates with non-GAAP EPS $2.55, revenue $8.3B, and raises full-year 2026 base business revenue guidance

• Q3 2026 product sales increased 13% to $8.3 billion, as reported by Gilead Sciences.
• Non-GAAP EPS was $2.55, up 3% YoY, on revenue of $8.3B, up 7% year over year.
• Quarterly beat driven by strong performance in its HIV franchise, while other business areas lag.

https://finviz.com/stock?t=GILD&p=d